Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the initiation of a clinical trial to evaluate the
combination of the companys investigational anti-PD-1 immunotherapy,
MK-3475, and GlaxoSmithKlines orally administered kinase inhibitor,
pazopanib, in advanced renal cell carcinoma.
Language:
English
Contact:
MerckMedia:Ian McConnell, 908-423-3046orClaire Mulhearn, 908-423-7425orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more